Saatja: <
[email protected]>
Saadetud: 25.06.2020 16:58
Teema: WHO: C.L.22.2020 (43rd ECDD)
Dear Member States of the World Health Organization,Please find attached,
in the six official languages, C.L.22.2020 regarding the 43rd Expert
Committee on Drug Dependance which will be held from 12 to 16 October
2020.Should you have questions regarding C.L.22.2020 please send an email
to
[email protected] regards,Department of Governing
BodiesWorld Health Organization
20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.22.2020
The World Health Organization (WHO) presents its compliments to Member States and
Associate Members and has the honour of announcing that the 43rd Expert Committee on Drug
Dependence (ECDD) will meet from 12 to 16 October 2020, in Geneva, Switzerland. In the
event that the meeting should be held virtually due to exceptional circumstances, corresponding
arrangements will be made. Given that ECDD meetings are of a closed nature, this letter serves
to notify Member States of the substances under review at the 43rd ECDD, which are in the
Annex I for reference.
WHO is mandated by the 1961 and 1971 International Drug Control Conventions to make
recommendations to the UN Secretary-General on the need for and level of international control
of psychoactive substances based on the advice of its independent scientific advisory body, the
ECDD. To assess the appropriate control of a psychoactive substance, the ECDD convenes
annually to review the potential of this substance to cause dependence, abuse and harm to health,
as well as any therapeutic applications. In order to perform this review and make scientific and
evidence-based decisions, the ECDD conducts medical, scientific, and public health evaluations
of the selected psychoactive substances using the best available information.
Although the meetings are of a closed nature, Member States are invited to contribute to
the ECDD review process by joining the 43rd ECDD Open Session on 12 October 2020. The
Open Session will allow interested parties to present information concerning substances under
review to the Expert Committee. Registration information will be made available on the ECDD
website: https://www.who.int/medicines/access/controlled-substances/en/.
… As in the past and in line with the publication “Guidance on the WHO review of
psychoactive substances for international control” (EB126/2010/REC1, Annex 6) 1, Member
States can also contribute to the ECDD review process by providing accurate information
concerning the substances under review in advance of the meeting. For this purpose, a
questionnaire will be sent to Member States to gather country information on the legitimate use,
harmful use, status of national control and potential impact of international control for each
substance under evaluation.
… Annex II to this Circular Letter contains a list of national focal points officially designated
by Member States in previous years who are approached to provide country information to the
ECDD. If the individual(s) on the list is(are) still the official focal point(s) to be contacted this
year for completing the ECDD Member State questionnaire, then no further action is required.
1
http://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=58.
... ENCLS: (2)
Page 2
C.L.22.2020
If the focal point(s) information require(s) changes or amendments, Member States are
invited to send an email to
[email protected] by 7 July 2020 with the subject
“43ECDD Focal Point: (Country Name)”. The Secretariat will provide the Member States with a
form to update this information.
If no additions or amendments to focal point(s) details are made by this date, the focal
point(s) from the list will be given further instructions and direct access to online questionnaires
by the WHO Secretariat. Once received, the completed questionnaires will be prepared as a
report as part of the 43rd ECDD substance review process.
In addition to the questionnaire, Member States are also encouraged to provide any
additional relevant information (unpublished or published) on substances to be reviewed by the
43rd ECDD by emailing
[email protected] with the subject “Ref: C.L.22.2020”.
The World Health Organization takes this opportunity to renew to Member States and
Associate Members the assurance of its highest consideration.
GENEVA, 23 June 2020
Annex I
43rd Expert Committee on Drug Dependence (ECDD)
12–16 October 2020
Substances for review
The substances listed below have never been formally reviewed by WHO and are not currently
under international control. Information was brought to WHO’s attention that these substances are
clandestinely manufactured, of especially serious risk to public health and society, and of no recognized
therapeutic use by any Party.
Synthetic opioids
Critical review:
1. Isotonitazene
Synthetic cannabinoid receptor agonists
Critical review:
2. MDMB-4en-PINACA
3. CUMYL-PEGACLONE
Benzodiazepines
Critical review:
4. Flubromazolam
5. Clonazolam
6. Diclazepam
Dissociative-type substances
Critical review:
7. 3-MeO-PCP
8. DIPHENIDINE
9. 2-MEO-DIPHENIDINE
Hallucinogen
Critical review:
10. 5-MEO-DALT
Synthetic stimulant
Critical review:
11. 3-FLUOROPHENMETRAZINE (3-FPM)
Annex 2
List of focal points designated by Member States in previous years
Country E-mail Name Focal Point Position Affiliation Comments
Afghanistan
[email protected] Shahpoor Yousuf
Albania
[email protected] Linda Ternova Specialist Regulation Sector of
Pharmaceutical Market and
Medical Devices
Algeria
[email protected] Ghrieb Houria Chargé du dossier des
stupéfiants, des
psychotropes et des
précurseurs chimiques
Andorra
[email protected] Carla Lobaco Valls Technical officer Department of Health
Resources and Medicines
Andorra
[email protected] Carme Pallarés Chief Department of Health
Papaseit Resources and Medicines
Angola
Antigua and Barbuda
Argentina
[email protected] G. Rebaldería Psicotrópicos Administración Nacional de
Medicamentos, Alimentos y
Tecnología
Armenia
[email protected] Hasmik Martirosyan Head Controlled Substances
Management Department
Australia
[email protected] Allison Jones
Australia
[email protected] Leila Jordan Director UN Health Section,
International and
Commonwealth/State
Relations Branch, Australian
Government Department of
Health
Austria
[email protected] Mag Raphael Bayer Deputy Head Federal Ministry of Labour,
Social Affairs, Health, and
Consumer Protection
1
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Azerbaijan
[email protected] Telman Suleyman
Oglu
Mammadhassanov
Bahamas
Bahrain
[email protected] Samar Yousef Salem
Bangladesh
[email protected] Md. Habibur Rahman Addl. Secretariat, Health Please confirm
Khan Services Division, Ministry email address
of Health and Family
Welfare
Barbados
[email protected] Maryam Hinds Director Barbados Drug Service
b
Belarus
[email protected] Aleksey Kralko
Belgium
[email protected] Peter Blankaert Epidemiology and public
health
Belize
Benin
[email protected] Hope Akohouvi Amou Pharmacien Diplômé Direction de la Pharmacie,
d’Etat du Médicament et des
Explorations Diagnostiques
Bhutan
[email protected] Dil Kumar Subba
Bolivia (Plurinational State of)
[email protected] Maria Julia Carrasco
Bosnia and Herzegovina
[email protected] Ana Cvijanović
Bosnia and Herzegovina
[email protected] Sabina Šahman Please confirm
email address
Botswana
[email protected] Vivian Sebako Chief Pharmacist Department of Clinical
Services
Brazil
[email protected] Maria Dilma Alves
Teodoro
2
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Brazil
[email protected] General Coordinator
for Mental Health,
Alcohol and other
drugs
Brazil
[email protected] Renata de Morais Controlled products National Health Surveillance
Souza manager Agency (Anvisa)
Brazil
[email protected] Controlled products National Health Surveillance Exceeds limit of
manager Agency (Anvisa) 3 focal points
Brunei Darussalam
[email protected] Hajah Rosni Haji Jair Director of
Pharmaceutical
Services
Bulgaria
[email protected] Slaveyka Nikolova Senior Expert at the
‘Health Promotion and
Prophylaxis of
Diseases and
Addictions’
Bulgaria
[email protected] Director National Focal Centre in the
National Centre of Narcotic
Addictions
Burkina Faso
[email protected]
Burundi
[email protected] Aimable Bizoza
Cabo Verde
[email protected] Fernanda Marques
Cambodia
[email protected] Chhit Sophal
Cameroon
[email protected] Ketchozo Loko Chef de Bureau des Please confirm
Wilfried Stupéfiants et des email address
Psychotropes
Canada hc.csd.international.dsc.sc@canad
a.ca
Central African Republic
3
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Chad
[email protected] Haoua Haroun Saker Please confirm
email address
Chile
[email protected] Javiera Erazo Leiva Psicóloga
China
[email protected] Deputy Director of National Narcotics
Division II Laboratory
China
[email protected] Wang Wei Officers from Office of National Narcotics
International Control Commission
Cooperation Division
China
[email protected] Senior Expert National Narcotics
Laboratory
Colombia
[email protected] Oscar Ricardo Santana Please confirm
email address
Colombia
[email protected] Coordinadora del Ministerio de Salud
Grupo de Convivencia
Social y Ciudadanía de
la Dirección de
Promoción y
Prevención
Colombia
[email protected] A. Peñuela Please confirm
email address
Comoros
Congo
[email protected] Ghislaine Mbelu Pharmacist
Kanyunya
Cook Islands
[email protected] Valentino Wichman
ov.ck
4
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Costa Rica
[email protected] Marchena Vasquez MD, External institute on alcoholism and
consultation, drug dependence
comprehensive care
center for minors
Côte d’Ivoire
[email protected] Ernest Zotoua Directeur
Coordonnateur du
Programme National
de Lutte contre le
Tabagisme, la
Toxicomanie et les
autres Addictions
Croatia
[email protected] Romana Katalinić
Cuba
Cyprus
[email protected] John Kkolos
Czechia
[email protected] Vlastimil Brandejs Unit of the Narcotics and
Psychotropic Substances
Inspectorate
Democratic People’s Republic Kim Jong Guk Section Chief, Drug
of Korea Supply and
Management
department
Democratic Republic of the
Congo
Denmark
[email protected] Maria Koch Aabel Danish Health Authority
Djibouti
Dominica
Dominican Republic
[email protected] Elizabeth Ruiz Please confirm
email address
Dominican Republic dalia.sanchez@ministeriodesalud. Francisca Dalia Please confirm
gob.do Castillo Sanchez email address
5
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Ecuador
[email protected] Enríquez Anaya Internal Management
of Mental Health and
Integral Prevention of
the Socioeconomic
Phenomenon of Drugs
Area
Ecuador
[email protected] Rojeab Bravo Analyst of the
transition process of
the "Drugs Technical
Secretariat" into a
Ministry of Health
attribution
Egypt
[email protected] Nahla Attia Ministry of Health Egypt
El Salvador
[email protected] José Mauricio
Bermúdez Recinos
Equatorial Guinea
Eritrea
[email protected] Michael Girmay Haile
Estonia
[email protected] Malle Tiidelepp Please confirm
email address
Estonia Katrin.Tomson- Katrin Tomson- Leading Specialist of Agency of Medicines of
[email protected] Johanson Department of Estonia
Inspection
Eswatini
Ethiopia
[email protected] Baharu Zewdie Moya Drug Dependency
Prevention and
Control
Fiji
[email protected] Apolosi Vosanibola
Finland
[email protected] Katja Pihlainen
France
[email protected] Aldine Fabreguettes
6
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Gabon
[email protected] Okouyi Ndakissa Senior Specialist,
Department of
Pharmaceutical
Activities
Gambia
Georgia
[email protected] Ketevan Gorozia
Germany
[email protected] Elke Lehmann
Ghana
[email protected] Martha Gyansa- Director,
Lutterodt Pharmaceutical
Services
Greece
[email protected] Ioanna Siamou
Grenada
Guatemala
[email protected] Erica Janeth Cohobon Departamento de
Lepe Regulacion y control
de productos
farmeuticos y afines
Guinea
Guinea-Bissau
Guyana
Haiti
[email protected] Marie Judith Robuste Chef de Service
Roche
Honduras
[email protected] Alex Virgilio Santos Director General Instituto Hondureño para la
Moreno Prevención del Alcoholismo,
Drogadicción y
Farmacodependencia
Hungary
[email protected] Tímea Kahlesz
Iceland
[email protected] Bjarni Sigurðsson Pharmacist Ministry of Health
India
[email protected]), Rakesh Chadda
7
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Indonesia
[email protected] Dra Agusdini Banun
Saptaningsih
Iran (Islamic Republic of)
[email protected] Abdehzadeh
Iran (Islamic Republic of)
[email protected] Alebouyeh
Iran (Islamic Republic of)
[email protected] Ahmad Hajebi Director General of Iran University of medical
Department for Mental sciences, department of
Health & Substance psychiatry; ReCARB
Abuse
Iraq
[email protected] Abdulghani National Advisor for Please confirm
mental health/ email address
Consultant Psychiatrist
Ireland
[email protected] Brennan Assistant Principal,
Department of Health
Ireland
[email protected] Byran Sheehan Higher Executive
Officer, Department of
Health
Israel
[email protected] Itamar Grotto Head of Public Health Ministry of Health
Services
Israel
[email protected] Tal Lavy The Component Authority
for Narcotics, Psychotropics,
and Precursors
Israel
[email protected] Adviser Permanent Mission of Israel
to the UN, Geneva
Italy
[email protected] Pietro Canuzzi Directorate General
for Health Prevention
Italy
[email protected] Rocco Signorile Ministry of Health
Jamaica
[email protected] Lishann Salmon Ministry of Health; Ministry
of Foreign Affairs and
Foreign Trade; Permanent
Mission of Jamaica to the
United Nations, Geneva
8
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Jamaica
[email protected] Winston De La Haye
Jamaica
[email protected] Michelle Walker
Japan
[email protected] Compliance and Narcotics
Division, Pharmaceutical
Safety and Environmental
Health Bureau
Jordan
[email protected] Heyam Wahbeh
Kazakhstan
[email protected] Prilutskaya Marina
Kenya
[email protected] Anthony Toroitich
g
Kenya
[email protected] Simon Njuguna
Kiribati
[email protected] Biribo Kararaiti
Kuwait
[email protected] Ali Abdulmohsen
Jaragh
Kyrgyzstan
[email protected] Kanyshai Damirbek
Lao People’s Democratic
[email protected] Khatthanaphone Head of Health Please confirm
Republic Phandoangsy Promotion and email address
Nutrition Unit
Latvia
[email protected] Linda Veisberga
Lebanon
[email protected] Marie-Therese Matar
Lesotho
[email protected] Masello Sello
Liberia
Libya
Lithuania
[email protected] Rima Mačiūnienė Head of the Drugs and
Psychotropic
Substances Precursors
Control and Risk
Assessment Division
9
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Luxembourg
[email protected] Alain Origer
Madagascar
[email protected] Mahavany Vénot Pharmacien Inspecteur
Amélie Nicole
Malawi
[email protected] Michael Udedi Assistant Director of Please confirm
Clinical Services email address
(Mental health and
substance abuse)
Malaysia
[email protected] Rohaida Binti Zakaria Senior Principle Ministry of Health
Assistant Director
Licensing Branch
(Controlled Sub-
Section), Pharmacy
Enforcement Division
Maldives
[email protected] Aishath Mohamed Deputy Director
General,
Pharmaceuticals;
Medicine and
Therapeutic Goods
Division
Mali
[email protected] Mahamadou Ousmane Chef de Section Direction de la Pharmacie
Maiga Reglementation
Malta
[email protected] Victor P. Pace
Marshall Islands
[email protected] Julia Alfred Secretary of Health Please confirm
email address
Mauritania
[email protected] Hamoud Fadel Directeur de la Ministère de la Santé
Yamohomed Pharmacie et du
Laboratoire
Mauritius
[email protected] Director health
Services (DHS)
Mauritius
[email protected] A. Jhugroo Adviser, Substance
Abuse
10
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Mexico
[email protected] David Correa Pina Verificador-
Dictaminador
Especializado
Micronesia (Federated States
[email protected] Benido Victor
of)
Monaco
[email protected] Isabelle Kessedjian
Mongolia
[email protected] Luvsandagva
Purevdorj
Montenegro
[email protected] Jasna Sekulic Head of the
Department for
prevention policy of
drug abuse
Morocco
[email protected] Hassan Elkarimi
Morocco
[email protected] Jallal Toufiq Directeur, OMDA,
CHU Ar-Razi, Salé
Mozambique
[email protected] Eugénia Guelfrida
Salesio Teodoro
Myanmar
[email protected] Nanda Myo Aung Program Drug Dependency
Wan Manager/Consultant Treatment and Research
Psychiatrist Unit, Department of Medical
Services
Myanmar
[email protected] Tin Wah Wah Win Deputy Director
(Drugs) / Department
of Food and Drug
Administration
Namibia
[email protected] Ester Mvula
Nauru
[email protected] Richard Leona
Nepal Demet
Aydınkarahaliloğlu
Netherlands
[email protected] Liefke Huizinga
11
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
New Zealand
[email protected] Emily Kay
New Zealand
[email protected] Lauren Bellamore Advisor (Drug Ministry of Health
Intelligence)
Nicaragua
[email protected] Karla Vanessa Directora de Farmacia
Delgado Martinez
Niger
[email protected] Haoua Na Allah Alou Chef de Division la Direction de la Pharmacie
Pharmacie et et de la Medecine
Medicaments Traditionnelle au Ministere
de la Sante Publique
Nigeria
[email protected] Rafiu Akanbi Folarin Head Narcotics and Please confirm
Drug Abuse email address
Niue
[email protected] Grizelda Mokoia
North Macedonia
Norway
[email protected] Anne S. Onsgård
Sagabråten
Oman
[email protected] Mahmood Al Abri
Pakistan
[email protected] Muhammad Arif
Palau
[email protected] Chief Pharmacist,
Chief of Ancillary
Services
Palau
[email protected]
Palau
[email protected] Marla Ito
Panama
Papua New Guinea
[email protected] Vicky Wari
Paraguay
Peru
[email protected] Judith Castañeda
Alcántara
Philippines
[email protected] Ivanhoe Escartin
12
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Poland
[email protected] Michał Kidawa National Bureau for Drug
Prevention
Portugal
[email protected] Graça Vilar Consultant Psychiatrist
Puerto Rico
Qatar
[email protected] Majid Ali Al Abdulla
Republic of Korea
[email protected] Mi Young Hyun
Republic of Moldova
[email protected] Stanislav Grosu
Romania
[email protected] Camelia Bunaciu
Russian Federation
[email protected] Olga Panova Deputy Head of Ministry of Health
Division, Department
of Drug Supply and
Medical devises
regulation
Rwanda
Saint Kitts and Nevis
Saint Lucia
[email protected] Donna Daniel Please confirm
email address
Saint Lucia
[email protected] Paul Caleb Programme Officer,
Substance Abuse Unit,
Department of Health
and Wellness
Saint Vincent and the
Grenadines
Samoa
[email protected] Robert Thomsen
San Marino
Sao Tome and Principe
Saudi Arabia
[email protected] Adnan Alshammary Saudi Food and Drug
Authority
13
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Senegal
[email protected] Bintou Dia
Serbia
[email protected] Nataša Savić
Seychelles
Sierra Leone
Singapore
[email protected] Ong Lay Tin Senior Executive Ministry of Health
(International
Cooperation) / Public
Health Group
Slovakia
[email protected] Jan Lehotsky Reitox National FP, Ministry of Health
Department of Anti-
Drug Strategy
Coordination and
Drug Monitoring
Slovenia
[email protected] Joze Hren
Solomon Islands
[email protected] Paul Orotaloa
Solomon Islands
[email protected] Stephen Araitewa
Somalia
South Africa
[email protected] MG Molewa Deputy Director
Inspectorate & Law
Enforcement
South Sudan
Spain
[email protected] Manuel Ibarra Jefe de Departamento Agencia Española de
de Inspección y Medicamentos y Productos
Control de Sanitarios
Medicamento
Spain
[email protected] Lidia Fernandez Jefe del Área de Agencia Española de
Matellano Estupefacientes y Medicamentos y Productos
Psicótropos Sanitarios
Sri Lanka
[email protected] BMW Balasooriya
14
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Sudan
Suriname
Sweden david.lorentzon@regeringskansliet David Lorentzon
.se
Switzerland
[email protected] Diane Steber
Syrian Arab Republic
[email protected] Ahmed Al-Salama Directorate of Mental
Health
Tajikistan
[email protected] Salim Abdulazizov
Thailand
[email protected] Chantharakul Pharmacist in Narcotics Control Division
Professional Level (Standards and Regulations
Sub-Division), Food And
Drug Administration,
Ministry of Public
Thailand
[email protected] Chavanich Pharmacist in Narcotics Control Division
Professional Level (Standards and Regulations
Sub-Division), Food And
Drug Administration,
Ministry of Public
Thailand
[email protected] Tontisirin Director of Narcotics Narcotics Control Division,
Control Division Food And Drug
Administration, Ministry of
Public Health
Timor-Leste
[email protected] Soares Henriques Official at the National Directorate for
Department of Pharmacy and Medicine
Authorisation and
Market's Introduction
Togo
[email protected] Mouhoudine Yerima Responsable de la Please confirm
pharmacovigilance email address
Tokelau
Tonga
[email protected] Melenaite Mahe
15
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
Trinidad and Tobago
[email protected] Rohit Doon Advisor, Health
Promotions and
Communications
Tunisia
Turkey
[email protected] Head of Department
for Pharmacovigilance
and the Substances
subject to control
Turkmenistan
Tuvalu
Uganda
[email protected] Hafsa Lukwata Senior Medical
Officer
Ukraine
[email protected] Liudmyla Deputy Director of the Ministry of Health of
Konoshevych State Agency "The Ukraine
Center for Mental
Health Monitoring of
Drugs and Alcohol"
Ukraine
[email protected] Viktoria Kurlova Head of the Ministry of Health of
Department of Ukraine
National Strategy and
Policy on the
Circulation of
Psychoactive
Substances of the State
Agency "Center for
Mental Health
Monitoring of Drugs
and Alcohol"
Ukraine
[email protected] Sergii Shum State Agency "The Center
for Mental Health
Monitoring of Drugs and
Alcohol"
United Arab Emirates
16
Annex 2
Country E-mail Name Focal Point Position Affiliation Comments
United Kingdom of Great
[email protected] Catherine Crawford
Britain and Northern Ireland
United Republic of Tanzania
[email protected] Martin White
United States of America
[email protected] Sara Maongezi
Uruguay
[email protected] Jim Hunter Senior Program Center for Drug Evaluation
Manager Controlled & Research
Substances
Uzbekistan
[email protected] Horacio Porciuncula Area programatica de
salud mental
Vanuatu
[email protected] Jerry Iaruel
Venezuela (Bolivarian Republic
of)
Viet Nam
[email protected] Mhin Tam Nguyen Head of Prevention Ministry of Health
Department, Viet Nam
Authority for
HIV/AIDS Control
Yemen
Zambia
[email protected] Nita Besa Please confirm
email address
Zimbabwe
[email protected] Eneti Siyame Mental Health
Manager
17